Back to today’s briefing

Story perspectives

Engineered Protein Offers New Hope for Cancer Therapy

9/25/2025

36 8

Summary

Story summary

Researchers at the University of Washington's Institute for Protein Design engineered a protein that shuts off interleukin-2, reducing toxic immune effects while preserving anti-cancer activity.
David Baker, a Nobel Laureate, and Adam Broerman led the Nature study.
The engineered protein alters protein complexes to enable precise control of immune signaling duration. Experiments in human cells indicate potential for cancer therapies.

1 of 1

Story summary

Researchers at the University of Washington's Institute for Protein Design engineered a protein that shuts off interleukin-2, reducing toxic immune effects while preserving anti-cancer activity.
David Baker, a Nobel Laureate, and Adam Broerman led the Nature study.
The engineered protein alters protein complexes to enable precise control of immune signaling duration. Experiments in human cells indicate potential for cancer therapies.